Bristol-Myers Squibb Live Stock Price Today, Share Analysis and Chart

Name: Bristol-Myers Squibb Co.: Is Infosys Ltd. worth buying?
Item: Bristol-Myers Squibb Co.
Rating: 2.717791625
Author: Trendlyne DVM scores

Mid-range Performer

about

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol deriv...

54.65 -0.29 (-0.53%)

28.53% Gain from 52W Low

9.7M

XNYS Volume

XNYS 23 Jan, 2026 4:30 PM (EST)

Board Meeting

The next board meeting for Bristol-Myers Squibb is on 05 Feb 2026 for the purpose of Bristol-Myers Squibb Co Fourth Quarter Earnings Result for 2025 See details

Medium Financial Strength

50.0 / 100

Affordable Valuation

58.3 / 100

Technically Neutral

59.1 / 100

Mid-range Performer These stocks have affordable valuations, but mid range financials and momentum View Similar Embed DVM

1Yr Price target upside is 4%

23 analysts

Bristol-Myers Squibb Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Bristol-Myers Squibb Live Stock Price Today, Share Analysis and Chart

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol deriv...

28.53% Gain from 52W Low

SWOT Analysis

Bristol-Myers Squibb Live Price Chart